BrainStorm (BCLI) retains PharmaNet to assist in Development of Protocol for FDA Approval

QualityStocks would like to highlight BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases.

In the company’s news Friday,

BrainStorm has signed an agreement with PharmaNet LLC, a global drug development services provider, to help Brainstorm develop protocol and IND file for submission to the U.S. FDA for approval of BrainStorm’s amyotrophic lateral sclerosis (ALS) in human clinical trials.

The FDA has already granted Orphan Drug Designation for BrainStorm’s NurOwn™ treatment for ALS, and the company’s deal with PharmaNet brings the company one step closer to receiving FDA approval for human clinical trials in the United States.

Dr. Joyce L. Frey-Vasconcells will head up the efforts on behalf of PharmaNet, bringing to the table years of expertise in cell therapy, gene therapy, as well as experience working at the FDA as the deputy director for the Office of Cellular, Tissue and Gene Therapies with the Center of Biologics Evaluation and Research. Dr. Frey-Vasconcells currently serves as the executive director of PharmaNet Consulting.

“Dr. Frey-Vasconcells brings a wealth of knowledge to the development of our protocol and IND file for submission to the FDA,” Dr. Adrian Harel acting CEO of BrainStorm stated in the press release. “I am extremely pleased to have her join our expert team.”

NurOwn has demonstrated ability to process adult human mesenchymal stem cells found in bone marrow; these cells are capable of self-renewal, as well as differentiation into many cell types, making them a focus of regenerative therapy.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.